Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age

Human Molecular Genetics

Volumn 21, Issue 11, 2012, Pages 2599-2609

  Matthes, Frank ^a   Stroobants, Stijn ^b   Gerlach, Debora ^a   Wohlenberg, Claudia ^a   Wessig, Carsten ^c   Fogh, Jens ^d   Gieselmann, Volkmar ^a   Eckhardt, Matthias ^a   D'Hooge, Rudi ^b   Matzner, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Zymenex AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROSIDE SULFATASE; SULFATIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; ENZYME REPLACEMENT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LIPID BRAIN LEVEL; MALE; METACHROMATIC LEUKODYSTROPHY; MOUSE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; CEREBROSIDE-SULFATASE; CHO CELLS; CRICETINAE; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; GENETIC THERAPY; LEUKODYSTROPHY, METACHROMATIC; MICE; MICE, KNOCKOUT; TRANSFECTION; TREATMENT OUTCOME;

MUS;

EID: 84861114185     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds086     Document Type: Article

References (33)

1. von Figura, K., Gieselmann, V. and Jaeken, J. (2001). Metachromatic leukodystrophy. In Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Childs, B., Kinzler, K.W. and Vogelstein, B. (eds), The Metabolic and Molecular Bases of Inherited Disease. Mc Graw-Hill, New York,3695-3724.
2. Gieselmann, V. and Krägeloh-Mann, I. (2010) Metachromatic leukodystrophy-an update. Neuropediatrics, 41, 1-6.
3. Matzner, U., Herbst, E., Hedayati, K.K., Lüllmann-Rauch, R., Wessig, C., Schröder, S., Eistrup, C., Möller, C., Fogh, J. and Gieselmann, V. (2005) Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum. Mol. Genet., 14, 1139-1152.
4. Matzner, U., Lüllmann-Rauch, R., Stroobants, S., Andersson, C., Weigelt, C., Eistrup, C., Fogh, J., D'Hooge, R. and Gieselmann, V. (2009) Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol. Ther., 17, 600-606.
5. Beck, M. (2010) Therapy for lysosomal storage disorders. IUBMB Life, 62, 33-40.
6. Matthes, F., Wö lte, P., Böckenhoff, A., Hüwel, S., Schulz, M., Hyden, P., Fogh, J., Gieselmann, V., Galla, H.J. and Matzner, U. (2011) Transport of arylsulfatase A across the blood-brain barrier in vitro. J. Biol. Chem., 286, 17487-17494.
7. van der Beek, N.A., Hagemans, M.L., van der Ploeg, A.T., Reuser, A.J. and van Doorn, P.A. (2006) Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta Neurol. Belg., 106, 82-86.
8. Kishnani, P.S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W.L., Leslie, N., Levine, J., Spencer, C., McDonald, M. et al. (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology, 68, 99-109.
9. Sands, M.S., Vogler, C., Kyle, J.W., Grubb, J.H., Levy, B., Galvin, N., Sly, W.S. and Birkenmeier, E.H. (1994) Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J. Clin. Invest., 93, 2324-2331.
10. Vogler, C., Levy, B., Galvin, N.J., Thorpe, C., Sands, M.S., Barker, J.E., Baty, J., Birkenmeier, E.H. and Sly, W.S. (1999) Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr. Res., 45, 838-844.
11. Gliddon, B.L. and Hopwood, J.J. (2004) Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Pediatr. Res., 56, 65-72.
12. Urayama, A., Grubb, J.H., Sly, W.S. and Banks, W.A. (2004) Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc. Natl Acad. Sci. USA, 101, 12658-12663.
13. Urayama, A., Grubb, J.H., Sly, W.S. and Banks, W.A. (2008) Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol. Ther., 16, 1261-1266.
14. Dunder, U., Valtonen, P., Kelo, E. and Mononen, I. (2010) Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice. J. Inherit. Metab. Dis., 33, 611-617.
15. Tomatsu, S., Montaño, A.M., Dung, V.C., Ohashi, A., Oikawa, H., Oguma, T., Orii, T., Barrera, L. and Sly, W.S. (2010) Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol. Ther., 18, 1094-1102.
16. Kornfeld, S. (1992) Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu. Rev. Biochem., 61, 307-330.
17. Hess, B., Saftig, P., Hartmann, D., Coenen, R., Lüllmann-Rauch, R., Goebel, H.H., Evers, M., von Figura, K., D'Hooge, R., Nagels, G. et al. (1996) Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc. Natl Acad. Sci. USA, 93, 14821-14826.
18. Ramakrishnan, H., Hedayati, K.K., Lüllmann-Rauch, R., Wessig, C., Fewou, S.N., Maier, H., Goebel, H.H., Gieselmann, V. and Eckhardt, M. (2007) Increasing sulfatide synthesis in myelin-forming cells of arylsulfatase A-deficient mice causes demyelination and neurological symptoms reminiscent of human metachromatic leukodystrophy. J. Neurosci., 27, 9482-9490.
19. Matzner, U., Matthes, F., Herbst, E., Lüllmann-Rauch, R., Callaerts-Vegh, Z., D'Hooge, R., Weigelt, C., Eistrup, C., Fogh, J. and Gieselmann, V. (2007) Induction of tolerance to human arylsulfatase A in a mouse model of metachromatic leukodystrophy. Mol. Med., 13, 471-479.
20. Scott, J.E. and Dorling, J. (1965) Differential staining of acid glycosaminoglycans (mucopolysaccharides) by alcian blue in salt solutions. Histochemie, 5, 221-233.
21. Lüllmann-Rauch, R., Matzner, U., Franken, S., Hartmann, D. and Gieselmann, V. (2001) Lysosomal sulfoglycolipid storage in the kidneys of mice deficient for arylsulfatase A (ASA) and of double-knockout micedeficient for ASA and galactosylceramide synthase. Histochem. Cell Biol., 116, 161-169.
22. Wittke, D., Hartmann, D., Gieselmann, V. and Lullmann-Rauch, R. (2004) Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distribution. Acta Neuropathol. (Berl.), 108, 261-271.
23. Stroobants, S., Gerlach, D., Matthes, F., Hartmann, D., Fogh, J., Gieselmann, V., D'Hooge, R. and Matzner, U. (2011) Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Hum. Mol. Genet., 20, 2760-2769.
24. Stroobants, S., Leroy, T., Eckhardt, M., Aerts, J.M., Berckmans, D. and D'Hooge, R. (2008) Early signs of neurolipidosis-related behavioural alterations in a murine model of metachromatic leukodystrophy. Behav. Brain Res., 189, 306-316.
25. Matzner, U., Matthes, F., Weigelt, C., Andersson, C., Eistrup, C., Fogh, J. and Gieselmann, V. (2008) Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease. J. Mol. Med., 86, 433-442.
26. Kolter, T. and Sandhoff, K. (2010) Lysosomal degradation of membrane lipids. FEBS Lett., 584, 1700-1712.
27. Kehrer, C., Blumenstock, G., Raabe, C. and Krägeloh-Mann, I. (2011) Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy. Dev. Med. Child Neurol., 53, 156-160.
28. Kehrer, C., Blumenstock, G., Gieselmann, V. and Krägeloh-Mann, I (2011) The natural course of gross motor deterioration in metachromatic leukodystrophy. Dev. Med. Child Neurol., 53, 850-855.
29. i Dali, C. and Lund, A.M. (2009) Intravenous enzyme replacement therapy for metachromatic leukodystrophy (MLD). Abstract from the Annual Clinical Genetics (ACMG) Meeting on 25 March 2009 in Tampa, FL. http://mldfoundation.org/pdfs/Shire-ERT-P12-2009-02.pdf.
30. Schröder, S., Matthes, F., Hyden, P., Andersson, C., Fogh, J., Müller-Loennies, S., Braulke, T., Gieselmann, V. and Matzner, U. (2010) Site-specific analysis of N-linked oligosaccharides of recombinant lysosomal arylsulfatase A produced in different cell lines. Glycobiology, 20, 248-259.
31. Baum, H., Dodgson, K.S. and Spencer, B. (1959) The assay of aryl sulfatase A and B in human urine. Clin. Chim. Acta, 4, 453-455.
32. Bremer, J., Baumann, F., Tiberi, C., Wessig, C., Fischer, H., Schwarz, P., Steele, A.D., Toyka, K.V., Nave, K.A., Weis, J. and Aguzzi, A. (2010) Axonal prion protein is required for peripheral myelin maintenance. Nat. Neurosci., 13, 310-318.
33. Paxinos, G. and Franklin, K.B.J. (2001) The Mouse Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, San Diego, CA